|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02279 YONGHE MEDICAL
Nominal 
0.790 +0.010 (+1.282%) | 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 900,203 | 8.746% | 1,777,258 | 1,412,791 | 2,168,580 | 1,638,297 |
| Cost of Sales | (370,766) | 2.931% | (780,072) | (540,212) | (588,604) | (416,667) |
| Gross Profit | 529,437 | 13.225% | 997,186 | 872,579 | 1,579,976 | 1,221,630 |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (80) | -71.014% | (257) | (138) | 153 | (487) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | (146,699) | -42.791% | (585,219) | (109,466) | 210,276 | 230,914 | |
| Taxation | 8,051 | -73.374% | 38,535 | 23,608 | (90,088) | (67,582) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 76 | -- | 290 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (138,572) | -38.737% | (546,394) | (85,858) | 120,188 | 163,332 | |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 16,050 | -48.715% | 53,469 | (52,155) | 45,819 | 35,347 |
| Depreciation & Amortisation | 168,575 | 10.817% | 334,840 | 224,672 | 200,975 | 159,125 |
| Directors' Emoluments | -- | -- | 4,456 | 4,085 | 2,344 | 5,703 |
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | -28.000 | -36.364% | -108.000 | -16.000 | 29.000 | 39.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 7.600 | -- |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | 26.207% | -- |
| Cash flow per share ($) | -- | -- | (0.035) | (0.212) | 1.091 | 1.334 |
| NBV per share ($) | 1.526 | -- | 1.788 | 3.008 | 3.266 | -- |
| Remarks: | Real time quote last updated: 15/11/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB -138,572,000 |
| %Change | -38.737% |
| EPS / (LPS) | RMB -0.280 |
| NBV Per Share (¥) | RMB 1.526 |